3,5-Diiodothyropropionic acid

Name: 3,5-Diiodothyropropionic acid
Brand: MedChemExpress
SKU: HY-126236
Rating: 4.5 (1 reviews)

Cat. No.: HY-126236 Purity: 98.34%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with K_a of 2.40 and 4.06 M^-1 for TRα1 and TRβ1, respectively. 3,5-Diiodothyropropionic acid promotes angiogenesis in 3-D human dermal microvascular endothelial cell sprouting assay. 3,5-Diiodothyropropionic acid prevents myocardial arteriolar loss in thyroidectomized rats and enhances cardiac energy-generating capacity in postinfarction heart failure rats. 3,5-Diiodothyropropionic can be used in studies related to angiogenesis and heart failure.

For research use only. We do not sell to patients.

3,5-Diiodothyropropionic acid Chemical Structure

CAS No. : 1158-10-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	Get quote	Estimated Time of Arrival: December 31
50 mg	Get quote	Estimated Time of Arrival: December 31

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 3,5-Diiodothyropropionic acid:

3,5-Diiodothyropropionic acid (Standard) Get quote

1 Publications Citing Use of MCE 3,5-Diiodothyropropionic acid

•Environ Sci Technol. 2025 Mar 11;59(9):4530-4539. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

3,5-Diiodothyropropionic acid (0.1 μM) promotes angiogenesis in 3-D human dermal microvascular endothelial cell sprouting assay, with 2.1-fold increase in migrated cells and 2.0-fold increase in microvessel length ^[4].
3,5-Diiodothyropropionic acid (0.1 mM, 3 days) stimulates angiogenesis in 10-day-old chick embryo chorioallantoic membrane^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

3,5-Diiodothyropropionic acid (80 mg/60-day release pellets, via subcutaneous slow-release pellets, 6 weeks) prevents myocardial arteriolar loss in thyroidectomized rats^[2].
3,5-Diiodothyropropionic acid (375 μg/100 g, subcutaneous injection, once daily, 10 days) improves energy-generating capacity of the heart, and returns most downregulated metabolic genes toward normal in postinfarction heart failure rats^[3].
3,5-Diiodothyropropionic acid (375 μg/100 g, subcutaneous injection once daily for 10 days, with Captopril (HY-B0368) 2 g/L in drinking water for 21 days) improves cardiac energy-generating capacity, and returns more genes toward normal compared to used alone in postinfarction heart failure rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Thyroidectomized male Sprague-Dawley rats (10.5 weeks old)^[2]
Dosage:	80 mg/60-day release pellets
Administration:	Via subcutaneous slow-release pellets for 6 weeks
Result:	Prevented a 31% reduction in myocardial arteriolar length density in thyroidectomized Sprague-Dawley rats, with the 5-15 μm arterioles well preserved. Failed to prevent hypothyroidism-induced decreases in body temperature, body weight gain, heart weight and heart weight-to-body weight ratio. Did not improve cardiac function parameters including posterior wall thickness, fractional shortening, +dP/dt, -dP/dt, and heart rate. Increased serum triiodothyronine (T3) levels but kept serum thyroxine (T4) levels as low as the placebo group.

Animal Model:	Adult male Spraque-Dawley rats (175-275 g) were anesthetized with methoxyflurane, subjected to left thoracotomy, and a ligature was placed around the proximal left coronary artery to induce myocardial infarction^[3]
Dosage:	375 μg/100 g
Administration:	Subcutaneous injection once daily for 10 days
Result:	Reversed the downregulation of most metabolic genes. Restored the energy-generating capacity of the heart. Improved cardiac function as evidenced by reduced left ventricular end-diastolic pressure.

Animal Model:	Adult male Spraque-Dawley rats (175-275 g) were anesthetized with methoxyflurane, subjected to left thoracotomy, and a ligature was placed around the proximal left coronary artery to induce myocardial infarction ^[3]
Dosage:	375 μg/100 g
Administration:	Subcutaneous injection once daily for 10 days, with Captopril (HY-B0368) 2 g/L in drinking water for 21 days
Result:	Reversed the downregulation of metabolic enzymes. Restored the energy-generating capacity of the heart. Improved cardiac function as evidenced by more genes returning toward normal compared to used alone.

Molecular Weight

510.06

Formula

C₁₅H₁₂I₂O₄

CAS No.

1158-10-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (98.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9606 mL	9.8028 mL	19.6055 mL
5 mM	0.3921 mL	1.9606 mL	3.9211 mL
10 mM	0.1961 mL	0.9803 mL	1.9606 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.20%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (244 KB) HNMR (257 KB) LCMS (254 KB) Elemental Analysis Report (102 KB)

Handling Instructions (2659 KB)

References

[1]. Pennock GD, et al. Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther. 1992 Oct;263(1):163-9. [Content Brief]

[2]. Liu Y, et al. Thyroid hormone analog 3,5-diiodothyropropionic acid promotes healthy vasculature in the adult myocardium independent of thyroid effects on cardiac function. Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1551-7. [Content Brief]

[3]. Maitra N, et al. Regulation of gene expression in rats with heart failure treated with the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) and the combination of DITPA and captopril. J Cardiovasc Pharmacol. 2007 Nov;50(5):526-34. [Content Brief]

[4]. Mousa SA, et al. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology. 2006 Apr;147(4):1602-7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9606 mL	9.8028 mL	19.6055 mL	49.0138 mL
	5 mM	0.3921 mL	1.9606 mL	3.9211 mL	9.8028 mL
	10 mM	0.1961 mL	0.9803 mL	1.9606 mL	4.9014 mL
	15 mM	0.1307 mL	0.6535 mL	1.3070 mL	3.2676 mL
	20 mM	0.0980 mL	0.4901 mL	0.9803 mL	2.4507 mL
	25 mM	0.0784 mL	0.3921 mL	0.7842 mL	1.9606 mL
	30 mM	0.0654 mL	0.3268 mL	0.6535 mL	1.6338 mL
	40 mM	0.0490 mL	0.2451 mL	0.4901 mL	1.2253 mL
	50 mM	0.0392 mL	0.1961 mL	0.3921 mL	0.9803 mL
	60 mM	0.0327 mL	0.1634 mL	0.3268 mL	0.8169 mL
	80 mM	0.0245 mL	0.1225 mL	0.2451 mL	0.6127 mL